This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Peter W. Schineller Joins Alexza Pharmaceuticals As Senior Vice President And Chief Commercial Officer

Stocks in this article: ALXA





MOUNTAIN VIEW, Calif., March 13, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Peter W. Schineller has joined the company as Senior Vice President and Chief Commercial Officer. 

Mr. Schineller brings more than twenty years of industry experience directing sales and marketing efforts at multinational pharmaceutical and specialty pharmaceutical companies for numerous diagnostic and therapeutic products.  In this newly created role, Mr. Schineller will be responsible for overseeing Alexza's global commercialization efforts and strategies for ADASUVE ®, reporting to Thomas B. King, Alexza's President and Chief Executive Officer.

"With the recent approval of ADASUVE in the US and EU, this is an exciting time to join the talented team at Alexza," said Mr. Schineller.  "Alexza is putting in place a number of important launch preparatory activities, and we are focused on having the elements we believe will support a successful commercial launch of ADASUVE in the U.S. and in Europe."

"We are very pleased to welcome Peter to Alexza as a member of our management team.  He brings a wealth of commercial experience in many settings and with many products," said Thomas B. King, Alexza President and CEO.  "The approvals of ADASUVE in the U.S. and the EU now make ADASUVE a global brand.  Peter will lead our commercialization strategies for ADASUVE as we focus on product launches later this year.  Moreover, Peter's diverse experience in introducing and promoting healthcare products is a great fit for contributing to Alexza and shaping our product pipeline opportunities."

Mr. Schineller was most recently Senior Vice President and General Manager at Ventana Medical Systems, a diagnostic company owned by Roche.  From August 2011 to September 2012, Mr. Schineller was a Principal at the Fidelis Consulting Group, providing commercial consulting expertise to the healthcare industry.  From July 2010 to July 2011, Mr. Schineller was Senior Vice President Sales, Marketing and Commercial Operations at Genoptix Medical Laboratories, a diagnostic company, which was acquired by Novartis.  From July 2008 to July 2010, Mr. Schineller was with Cypress Bioscience, a pharmaceutical company, serving as its Vice President Sales, Diagnostic Marketing and Managed Healthcare from August 2008.  From November 2002 to June 2008, Mr. Schineller was Co-Founder and Senior Vice President, Sales and Marketing at Verus Pharmaceuticals, and he has also previously held positions at Elan Biopharmaceuticals, Inc., Dura Pharmaceuticals, Inc. and Abbott Laboratories, Inc.  Prior to entering the healthcare industry, Mr. Schineller served as a Commissioned Officer in the United States Marine Corps where he attained the rank of Captain.  Mr. Schineller holds a BA degree from the State University of New York at Stony Brook.



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,807.24 +88.24 0.50%
S&P 500 2,061.98 +9.23 0.45%
NASDAQ 4,717.9250 +16.0580 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs